Home > Boards > US OTC > Cannabis > RushNet Inc. (RSHN)

NEWS NEWS NEWS Premier Biomedical Signs Joint Venture

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
getmoreshares Member Profile
Member Level 
Followed By 352
Posts 44,979
Boards Moderated 9
Alias Born 07/22/09
160x600 placeholder
getmoreshares Member Level  Tuesday, 07/30/19 10:18:41 AM
Re: None
Post # of 129862 
NEWS NEWS NEWS Premier Biomedical Signs Joint Venture Agreement With New Earth Development, RushNet Inc., and XYZ Hemp, Inc. to Market New Anti-Addiction Patch

JACKSON CENTER, PA / ACCESSWIRE / July 30, 2019 / Premier Biomedical, Inc. (OTCQB: BIEI) announced today the signing of an agreement forming a joint venture with New Earth Development Corporation, RushNet, Inc., and XYZ Hemp, Inc. to manufacture, market and sell a revolutionary Anti-Addiction Patch containing Premier Biomedical’s patented natural and synthetic formulation. The product will be based on the topical pain relieving patch technology currently marketed by Premier Biomedical. Because of the current focus on the opioid drug overdose epidemic, not only in the United States, but worldwide, the joint venture will quickly seek to expand sales globally.

Joshua Spooner, CEO of New Earth Development Corporation and Chief Scientific Officer of XYZ Hemp, Inc., is quoted as saying “our specially formulated hemp oil extracts with a patented formulation to increase skin penetration and bioavailability makes this a powerful and unique blend.”

Dr. Mitchell Felder, Chairman of the Board of Premier Biomedical, stated, “The Anti-Addiction Patch is a proprietary blend of natural components, including hemp oil extracts and a patented combination (US Pat. # 8865733) of Naltrexone and Cyclobenzaprine, two long-time FDA approved drugs. These medications are extremely well documented in the prevention and treatment of narcotic addiction.

“This is believed to be a revolutionary and efficacious treatment for opioid addiction. We anticipate no negative side-effects due to its intended topical delivery system, yet it would allow for both the outpatient and inpatient treatment. The topical patch is designed to provide a steady release of Naltrexone with an increased penetration and bioavailability of the product via a proprietary blend of components and the topical delivery system. The blend of hemp oil extracts along with Naltrexone and Cyclobenzaprine is expected to eliminate a desire for opioid abuse. The Anti-Addiction Patch will be prescribed to prophylactically protect a patient from an opioid-induced drug overdose, while simultaneously reducing the ability of the drug-addicted patient to achieve an opioid-induced high. Each patch is designed to provide continuous treatment for up to 7-10 days.”

William A. Hartman, President and CEO of Premier Biomedical, commented, “The Anti-Addiction Patch utilizes synergistic technologies from both the Biologics and Pain Management Divisions of Premier Biomedical and is intended to alleviate the drug overdose problem which claims hundreds of victim per week in the USA alone. Initial sales efforts of the revolutionary Anti-Addiction Patch will target addiction clinics and rehab centers as well as government agencies at both the Federal and State levels. Our plan is to quickly branch out beyond the domestic market after a successful launch in the United States.”

“The new group has already held a meeting with a major multi-faceted defense contractor, and interest was expressed not only in the proposed Anti-Addiction Patch, but also in Premier’s treatment and potential cure for PTSD. Subsequent meetings are being scheduled with this major corporation as well as others to develop and exploit these promising technologies.”

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist